Drug Profile
ACT 280778
Alternative Names: ACT-280778Latest Information Update: 27 Jun 2017
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Class Antihypertensives
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Essential hypertension
Most Recent Events
- 16 Jun 2017 Actelion Pharmaceuticals was acquired by Janssen Pharmaceuticals
- 19 Apr 2012 Discontinued - Phase-II for Essential hypertension in Israel (PO)
- 19 Apr 2012 Discontinued - Phase-II for Essential hypertension in Serbia (PO)